Sankyo Company
E345804
Sankyo Company is a Japanese pharmaceutical firm known for its role in developing cholesterol-lowering statin drugs and later becoming part of Daiichi Sankyo.
All labels observed (1)
| Label | Occurrences |
|---|---|
| Sankyo Company canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T3308730 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Sankyo Company Context triple: [Akira Endo, employer, Sankyo Company]
-
A.
Chugai Pharmaceutical
Chugai Pharmaceutical is a major Japanese research-based pharmaceutical company known for its innovative biopharmaceuticals and strategic alliance with Roche.
-
B.
Eisai
Eisai is a Japanese pharmaceutical company known for developing treatments in neurology and oncology, including Alzheimer’s disease therapies.
-
C.
Yoshimoto Kogyo
Yoshimoto Kogyo is a major Japanese entertainment conglomerate best known for managing comedians and producing comedy shows, theater, television, and other media.
-
D.
Keio Corporation
Keio Corporation is a major Japanese private railway and transportation company operating rail lines and related services in the Tokyo metropolitan area.
-
E.
Takenaka Corporation
Takenaka Corporation is a major Japanese architecture, engineering, and construction firm known for designing and building prominent structures domestically and internationally.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Sankyo Company Target entity description: Sankyo Company is a Japanese pharmaceutical firm known for its role in developing cholesterol-lowering statin drugs and later becoming part of Daiichi Sankyo.
-
A.
Chugai Pharmaceutical
Chugai Pharmaceutical is a major Japanese research-based pharmaceutical company known for its innovative biopharmaceuticals and strategic alliance with Roche.
-
B.
Eisai
Eisai is a Japanese pharmaceutical company known for developing treatments in neurology and oncology, including Alzheimer’s disease therapies.
-
C.
Yoshimoto Kogyo
Yoshimoto Kogyo is a major Japanese entertainment conglomerate best known for managing comedians and producing comedy shows, theater, television, and other media.
-
D.
Keio Corporation
Keio Corporation is a major Japanese private railway and transportation company operating rail lines and related services in the Tokyo metropolitan area.
-
E.
Takenaka Corporation
Takenaka Corporation is a major Japanese architecture, engineering, and construction firm known for designing and building prominent structures domestically and internationally.
- F. None of above. chosen
Statements (29)
| Predicate | Object |
|---|---|
| instanceOf |
Japanese company
ⓘ
pharmaceutical company ⓘ |
| country | Japan ⓘ |
| developed |
cholesterol-lowering drugs
ⓘ
statin drugs ⓘ |
| focusesOn |
cardiovascular disease treatments
ⓘ
metabolic disease treatments ⓘ |
| hasParentCompany | Daiichi Sankyo ⓘ |
| hasSuccessorOrganization | Daiichi Sankyo ⓘ |
| headquartersLocation | Tokyo ⓘ |
| industry |
biotechnology
ⓘ
pharmaceuticals ⓘ |
| knownFor |
cardiovascular medicines
ⓘ
development of cholesterol-lowering statin drugs ⓘ |
| locationCountry | Japan ⓘ |
| mergedInto | Daiichi Sankyo ⓘ |
| notableContribution | advancement of statin therapy for hypercholesterolemia ⓘ |
| operatedIn |
Japanese domestic pharmaceutical market
ⓘ
global pharmaceutical market ⓘ |
| partOf | Daiichi Sankyo ⓘ |
| productType |
pharmaceutical preparations
ⓘ
prescription drugs ⓘ |
| regionServed |
Japan
ⓘ
international markets ⓘ |
| researchArea |
cardiovascular pharmacology
ⓘ
drug discovery ⓘ lipid-lowering therapies ⓘ |
| successor | Daiichi Sankyo ⓘ |
| type | public company ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Sankyo Company Description of subject: Sankyo Company is a Japanese pharmaceutical firm known for its role in developing cholesterol-lowering statin drugs and later becoming part of Daiichi Sankyo.
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.